A Guideline H drug involvement clearance review begins with conduct, not a substance label. Illegal use, prescription misuse, purchase or distribution, a positive test, treatment history, and future intent are distinct facts under SEAD 4 and the SF-86. Put your history on the correct route before explaining it.

How does a Guideline H drug involvement clearance review start?

Name the conduct first. The official concern reaches illegal controlled-substance use, misuse of prescription or non-prescription drugs, and other substances used for impairment or contrary to their intended purpose. It is broader than a list of illegal drugs.

SEAD 4, Guideline H connects that conduct to reliability, trustworthiness, possible impairment, and willingness to follow laws, rules, and regulations. Paragraph 25 then identifies different potentially disqualifying conditions. A candidate-friendly review should preserve those differences.

Create one row for each episode or course of conduct, recording the substance, what you did, and approximate first and last dates. Add frequency, circumstances, legal or prescription status as understood at the time, and whether you held eligibility, access, or a sensitive position. Mark every estimate honestly.

Do not begin with “hard” versus “soft” drugs. Those labels do not answer the guideline. The SF-86 lists THC, including marijuana, and says Section 23 follows federal law even when conduct is permissible under state law. Read the form’s instruction and ask the sponsoring security office about an ambiguity.

How should use and prescription misuse be separated?

Illegal use concerns consuming a drug or controlled substance within the form’s scope. Prescription misuse concerns intentionally using prescription medication contrary to its authorized purpose or direction. A prescription in your name does not answer whether the use was misuse.

The publicly posted SF-86 illustrates the split. Section 23 asks separately about illegal drug use and intentional prescription-drug misuse. The use entry requests the substance, first and most recent use, nature and frequency, relevant job or clearance context, and future intent.

For prescription conduct, preserve the prescription label, prescribing period, relevant medical records, and instructions if available. Then describe the divergence precisely: extra doses, use after the authorized period, use for a different purpose, or use of another person’s medication. Do not diagnose yourself.

Guideline H also reaches misuse of non-prescription drugs and other substances used to cause impairment or inconsistently with their intended purpose. If your facts do not fit a familiar drug name, describe the product and conduct.

Where do purchase, possession, manufacture, and distribution go?

Put acquisition and movement in their own route. The SF-86 asks about illegal purchase, manufacture, cultivation, trafficking, production, transfer, shipping, receiving, handling, or sale separately from use. One event may require answers in both places.

Guideline H paragraph 25(c) separately identifies illegal possession, including cultivation, processing, manufacture, purchase, sale, or distribution, as well as possession of drug paraphernalia. Do not reduce distribution to commercial sale. Giving or transferring a substance may present a different fact pattern from personal consumption.

For each act, note your role. Who obtained the substance? Who paid? Did you carry, store, give, mail, grow, process, or sell it? Avoid group narratives such as “we had some at the house” when the question requires your conduct.

Section 23 says truthful responses, and information derived from them, will not be used as evidence against you in a later criminal proceeding. If you are worried about exposure from conduct outside what the form asks, talk to a lawyer before writing a long narrative, but answer the questions the form asks.

How do testing and treatment compliance differ?

Do not merge them. A positive test is a result; a diagnosis is a qualified professional’s conclusion; treatment is a course of care; noncompletion is conduct within that course. Guideline H lists them separately. Keep the source and status of each fact visible.

For a test, obtain the collection date, tested substance, laboratory result, confirmation information, reviewing official’s determination if one exists, and final employer or agency outcome. Do not call a screening result “false” unless the authoritative process reached that conclusion. Explain prescribed medication through the designated review channel.

For treatment, preserve the provider, dates, requirements, discharge status, aftercare, and any prognosis you are authorized to provide. The SF-86, revised November 2016, asks whether you were ever ordered, advised, or asked to seek counseling or treatment because of illegal drug use in Section 23.6. Section 23.7 separately asks whether you ever sought counseling or treatment voluntarily as a result of drug or controlled-substance use.

Guideline H identifies failure to complete professionally prescribed treatment as a potential concern. Its mitigation text, by contrast, refers to satisfactory completion, aftercare, no recurrence, and a favorable prognosis from a qualified medical professional. Document which of those facts the record establishes.

Why do recency, frequency, and circumstances matter?

They help distinguish an event from a pattern and assess recurrence. SEAD 4 identifies conduct that happened long ago, infrequently, or under circumstances making recurrence unlikely as possible mitigation. It does not publish a universal waiting period.

Write actual intervals and counts when you know them; label estimates when you do not. “Occasional” hides information. So does “a long time ago.” Compare your chronology against prior forms, interview notes, medical records, and court documents before submitting it.

Identify the setting, associates, reason, maturity, stressor, medical episode, access status, and what changed. If the event occurred while you held classified access or a sensitive position, say so when asked; Guideline H specifically identifies illegal use in that context.

The form’s future-intent question deserves a direct answer with a truthful explanation. Guideline H separately identifies expressed intent to continue or failure to commit clearly and convincingly to discontinuation. A vague promise drafted for the application is weaker than a supported account of actual change.

What are the mitigation routes under Guideline H?

Mitigation is a set of conditions to evaluate, not a checklist that guarantees approval. The main routes concern remoteness or infrequency, low recurrence, acknowledgment plus evidence of change and abstinence, ended prescription abuse after severe illness, and successful treatment with aftercare.

Evidence of change may include separation from drug-using contacts, avoiding the prior environment, a sustained pattern of abstinence, accurate self-reporting, and a signed abstinence statement when appropriate. Use only the facts that are true for you. Do not end relationships merely to create a document.

If prescription misuse followed a severe or prolonged illness, collect records showing the prescription and relevant medical period, then state when the misuse ended. The mitigating condition is not “a doctor once prescribed it.” It includes the illness context and cessation of abuse.

Treatment evidence should match the prescribed plan. Completion, aftercare compliance, no recurrence, and a favorable professional prognosis are separate facts. Protect medical privacy by using the authorized release and submission process rather than placing records in an ordinary application attachment.

For a broader discussion of how past use is analyzed, see obtaining or maintaining eligibility after prior drug use. DCSA’s adjudicator training on Guideline H, which candidates can also open, shows how the agency presents security concerns and mitigating conditions.

How do I crosswalk the history to SF-86 Section 23?

Use a private worksheet, then answer the exact current form. Map each row to use, illegal acquisition or transfer, clearance or public-safety context, prescription misuse, counseling or treatment, and any other displayed question. One row may map to several questions.

Do not let the general lookback from one question overwrite an “ever” question elsewhere. The publicly posted form demonstrates both structures. Your electronic questionnaire may have updated wording, so the screen you certify controls your response.

Reconcile all prior disclosures. If dates or frequencies differ, determine whether the earlier answer was an estimate, incomplete, or wrong. Explain a correction openly through the sponsoring security office. A precise correction is better than forcing new records to match an old mistake.

The detailed mechanics of the drug section are covered in SF-86 Section 23 drug-use reporting. For the adjudicative side, understanding Guideline H provides a companion explanation. Your immediate task is narrower: put every event in the correct conduct row and attach the record that proves its dates or outcome.

Frequently Asked Questions

Does Guideline H cover only illegal drugs?

No. Its concern also includes misuse of prescription and non-prescription drugs and other substances used for impairment or inconsistently with their intended purpose.

Is a positive drug test the same as admitting use?

No. A test result, an admission, and an adjudicative finding are distinct facts. Obtain the test and review records, then describe the final result accurately.

Do purchase and use belong in the same SF-86 answer?

Not necessarily. Section 23 presents separate questions for illegal use and specified acquisition, production, handling, transfer, and sale conduct. Answer every applicable question.

Does old or infrequent conduct automatically resolve the concern?

No. Remoteness, infrequency, circumstances, and recurrence are evaluated together with the whole person. The authorized adjudicative agency decides whether a concern is mitigated.

What should I do before completing Section 23?

Build a substance-by-substance, conduct-by-conduct chronology; compare it with prior disclosures and records; then follow the exact wording and timeframe on the current form.